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Abstract
Huntington’s disease (HD) is a neurodegenerative condition
characterized by pathology in the brain and peripheral tissues.
Hyperactivity of the innate immune system, due in part to NFjB
pathway dysregulation, is an early and active component of HD.
Evidence suggests targeting immune disruption may slow
disease progression. Laquinimod is an orally active
immunomodulator that down-regulates proinﬂammatory cyto-
kine production in peripheral blood mononuclear cells, and in
the brain down-regulates astrocytic and microglial activation by
modulating NFjB signalling. Laquinimod had beneﬁcial effects
on inﬂammation, brain atrophy and disease progression in
multiple sclerosis (MS) in two phase III clinical trials. This study
investigated the effects of laquinimod on hyperactive proinﬂam-
matory cytokine release and NFjB signalling in HD patient
myeloid cell cultures. Monocytes from manifest (manHD) and
pre-manifest (preHD) HD gene carriers and healthy volunteers
(HV) were treated with laquinimod and stimulated with
lipopolysaccharide. After 24 h pre-treatment with 5 lM laquin-
imod, manHD monocytes released lower levels of IL-1b, IL-5,
IL-8, IL-10, IL-13 and TNFa in response to stimulation. PreHD
monocytes released lower levels of IL-8, IL-10 and IL-13, with
no reduction observed in HV monocytes. The effects of
laquinimod on dysfunctional NFjB signalling in HD was
assessed by inhibitor of kappa B (IjB) degradation kinetics,
nuclear translocation of NFjB and interactions between IjB
kinase (IKK) and HTT, in HD myeloid cells. No differences were
observed between laquinimod-treated and untreated condi-
tions. These results provide evidence that laquinimod dampens
hyper-reactive cytokine release from manHD and preHD
monocytes, with a much reduced effect on HV monocytes.
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Huntington’s disease (HD) is a neurodegenerative condition
caused by a cytosine-adenine-guanine (CAG) repeat expan-
sion in exon 1 of the huntingtin gene (HTT) (The Hunting-
ton’s Disease Collaborative Research Group 1993) and is
characterized by progressive motor, cognitive and psychiatric
symptoms including involuntary movement disturbances,
dementia and depression. Symptoms display delayed onset
despite presence of mHTT throughout the entire lifetime, and
usually become manifest in middle age. Primary pathology
involves dysfunction and loss of the GABAergic medium
spiny neurons in the striatum as well as cortical neuronal
degeneration, and is hallmarked by presence of intra-nuclear
and cytoplasmic aggregates of mHTT. Many mechanisms
have been described to contribute to tissue damage leading to
neuronal degeneration in HD, including excitotoxicity,
mitochondrial dysfunction, production of free radicals,
impairment of protein degradation systems and transcrip-
tional dysregulation; leading to inﬂammatory processes that
cause microglial and astrocytic activation and neuronal loss
(Ross and Tabrizi 2011; Ellrichmann et al. 2013).
In the central nervous system (CNS), elevated levels of
inﬂammatory molecules are observed in postmortem HD
brain tissue (Bj€orkqvist et al. 2008). Substantial numbers of
activated microglia are seen in affected regions of the brain
such as the striatum and cortex (Sapp et al. 2001; Pavese
et al. 2006), and this correlates with loss of neuronal
function (Politis et al. 2011). Activated microglia are also
present in the brains of pre-symptomatic HD gene carriers
(Tai et al. 2007), and peripherally, inﬂammatory molecules
are elevated in blood plasma many years before disease onset
(Dalrymple et al. 2007; Bj€orkqvist et al. 2008; Wild et al.
2011), suggesting a possible active role of the innate immune
system during progression to symptomatic disease. Periph-
eral myeloid cells are the likely source of elevated systemic
levels of inﬂammatory molecules. HD patient monocytes and
macrophages produce increased levels of cytokines when
stimulated ex vivo (Bj€orkqvist et al. 2008), and are impaired
in their ability to migrate towards chemo-attractant stimuli
(Kwan et al. 2012b). These same dysfunctional phenotypes
are observed in both peripheral myeloid cells and microglia
isolated from HD mouse models (Bj€orkqvist et al. 2008),
suggesting that blood-derived myeloid cells may reﬂect the
pathological actions of microglia in the CNS in HD. It is also
possible that there is direct communication between the
peripheral immune system and the CNS in HD: peripheral
inhibition of kynurenine 3-monooxygenase, highly expressed
in peripheral immune cells, ameliorates neurodegeneration in
a HD mouse model by raising CNS levels of neuroprotective
metabolite kynurenic acid and preventing hyperactive
microglial activity (Zwilling et al. 2011).
Hyper-reactivity of the innate immune response in HD is
due partly to nuclear factor (NF)jB pathway dysregulation
(Khoshnan et al. 2004; Tr€ager et al. 2014). In HD myeloid
cells, dysregulation is observed upon activation of Toll-like
receptors (TLRs) using lipopolysaccharide (LPS), implicat-
ing a possible mechanism of dysfunctional signalling down-
stream of TLR4, the principal LPS receptor (Poltorak et al.
1998; Qureshi et al. 1999). In cultured cells expressing
mHTT and striatal cells from HD transgenic mice, mHTT
was found to interact with inhibitor of kappa B (IjB) kinase
(IKK) c subunit, leading to elevated NFjB activity and
increased NFjB-dependent gene expression (Khoshnan
et al. 2004). This was also observed in primary human
peripheral blood mononuclear cells (PBMCs), along with a
more rapid degradation of IjB following LPS stimulation in
HD monocytes compared to controls (Tr€ager et al. 2014).
While there are treatments that manage the severity of
symptoms in HD, there are no effective disease-modifying
therapies and consequently, novel approaches targeting
hyperactive immune cells have been investigated. Minocy-
cline, a caspase inhibitor, reduces IL-1b and inducible nitric
oxide synthase, and in the R6/2 mouse model of HD,
minocycline signiﬁcantly delayed disease progression (Chen
et al. 2000). A small study in HD patients has shown
minocycline to be safe and well tolerated (Thomas et al.
2004), however, the primary endpoint of a 25% improvement
in the total functional capacity score was not met in a
subsequent futility study (Huntington Study Group DOM-
INO Investigators 2010). More recently, dimethyl fumarate,
an immunomodulator approved as a treatment for relapsing-
remitting MS (Tecﬁdera, Biogen), has been shown to have
beneﬁcial effects on neuronal degeneration, motor functions
and survival time in R6/2 and YAC128 mouse models of
HD. Dimethyl fumarate is believed to exert its effects via
induction of nuclear factor E2-related factor 2, a transcription
factor which activates detoxiﬁcation pathways and subse-
quently protects against oxidative damage triggered by
inﬂammation (Ellrichmann et al. 2011).
Laquinimod is a novel oral immunomodulatory drug
which has been shown to reduce the proportion of astrocytes
with nuclear NFjB (p65/RelA) immune-reactivity in cupri-
zone-treated mice (Br€uck et al. 2012), and decrease cytokine
release from LPS-stimulated adult human microglia (Mishra
et al. 2014). Laquinimod effects on peripheral inﬂammatory
phenotypes have also been described. Laquinimod-treated
human PBMCs release lower levels of interleukin (IL)-17,
IL-3 and granulocyte colony-stimulating factor (Br€uck and
Wegner 2011). Mononuclear cells isolated from the spleen of
a laquinimod-treated MS rat model display evidence of a
shift from proinﬂammatory T helper (Th)1-activating to anti-
inﬂammatory and regulatory Th2/Th3-activating cytokine
expression proﬁle, with a laquinimod-induced change in
favour of the Th2 stimuli IL-4, IL-10 and transforming
growth factor beta (TGFb) and reductions in the Th1 stimuli
tumour necrosis factor alpha (TNFa) and IL-12 (Yang et al.
2004). Laquinimod has also been shown to promote splenic
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development of M2 polarized monocytes and dendritic cells
in mice, leading to reduced cellular production of Th1-
activating cytokines IL-6, IL-12 and TNFa with a corre-
sponding increase in Th2-activating anti-inﬂammatory IL-10
production (Schulze-Topphoff et al. 2012).
Affymetrix GeneChip arrays on PBMCs have shown
that laquinimod increases IjB expression whilst down-
stream NFjB genes are decreased (Gurevich et al. 2010),
and imaging ﬂow cytometry has shown laquinimod-
induced reduction in p65 translocation in primary murine
astrocytes (Br€uck et al. 2012), suggesting a potential role
of NFjB signalling in laquinimod mechanism of action. It
is therefore plausible that laquinimod could reverse the
hyperactive proinﬂammatory phenotype observed in HD
PBMCs, possibly by rescuing the dysfunctional NFjB
signalling in these cells. Intervention of peripheral inﬂam-
matory events has previously been shown to modulate
central neuropathology and disease progression in HD
(Zwilling et al. 2011; Bouchard et al. 2012; Kwan et al.
2012a), therefore an immunomodulatory drug such as
laquinimod is a potential candidate for slowing disease
progression in HD patients by affecting peripheral immune
cells. In addition, laquinimod has already been studied in
human immunomodulation and has a very good safety
proﬁle following clinical trials for the treatment of MS
(Comi et al. 2012; Filippi et al. 2014; Vollmer et al.
2014). Such studies have also provided evidence for
laquinimod-induced immunomodulation having beneﬁcial
effects on disease progression and brain atrophy in MS
(Comi et al. 2012). As inﬂammation has been implicated
in myelin, axonal and neuronal loss in HD pathology
(Ellrichmann et al. 2013), it is feasible that laquinimod
may slow disease progression and reduce brain atrophy
rate in HD through central and peripheral immunomodu-
latory mechanisms, as it has been shown to do in MS.
Therefore, the goal of this study was to determine whether
laquinimod down-regulates the hyper-reactive proinﬂamma-
tory phenotype of HD patient myeloid cells, and switches the
functional signatures of these cells away from M1 and
towards M2 polarization with a consequential shift in the
balance from Th1- to Th2-activating cytokine release. This is
the ﬁrst demonstration of the effects of laquinimod in HD
patient myeloid cells. The second aim was to elucidate a
possible mechanism of action of laquinimod in the periphery,
by assessing its possible effects on NFjB pathway dysreg-
ulation in HD patient myeloid cells. While a mechanism of
action involving the NFjB pathway has been shown in cells
of the CNS, it is not yet known whether laquinimod has the
same effect in the periphery. To this end, primary human
monocyte and macrophage cultures from HD patient sub-
groups and healthy volunteers were treated with laquinimod
in stimulated and non-stimulated conditions. Cytokine
release, IjB levels, NFjB translocation and IKKc-mHTT
interactions were examined.
Methods
Collection and classification of human samples
All human experiments were performed in accordance with the
Declaration of Helsinki and approved by University College London
(UCL)/UCL Hospitals Joint Research Ethics Committee. All blood
donors provided informed written consent for research on Hunting-
ton’s disease. Whole blood samples were collected from manifest
HD patients with early or moderate stage disease (manHD), pre-
manifest HD gene carriers (preHD) and healthy volunteers (HV).
ManHD samples were collected from six females and 13 males with
an average age of 55.32 years ranging from 27 to 70; preHD
samples were collected from six females and three males with an
average age of 47.45 years ranging from 33 to 62; HV samples were
collected from 10 females and ﬁve males with an average age of
47.95 years ranging from 25 to 68.
Primary human monocyte isolation
Whole blood samples were decanted into 50 mL heparinized tubes
(50 lL prescription grade heparin in standard 50 mL Falcon tubes).
25 mL whole blood was then carefully layered onto 20 mL
Histopaque-1077 (Sigma, Dorset, UK) and separated through the
gradient by centrifugation in a swinging bucket rotor at 400 g for
30 min at 21°C with no brake. The resulting PBMC layer was
removed with a Pasteur pipette from the plasma/Histopaque-1077
interface. PBMCs were washed in magnetic-activated cell sorting
(MACS) buffer [1 9 Dulbecco’s phosphate-buffered saline (Gibco,
Life Technologies, Paisley, UK); 0.5% bovine serum albumin
(Sigma); 2 mM EDTA (Sigma)] and pelleted out of wash solution
by centrifugation at 350 g for 10 min at 4°C. Cells were re-
suspended in 1 mL MACS buffer and 60 lL anti-CD14 MACS
MicroBeads (Miltenyi Biotec, Surrey, UK) was added to the
suspension, followed by quick vortex and 15 min incubation at 4°C.
Cells were then pelleted by centrifugation at 350 g for 5 min at 4°C,
and re-suspended in fresh MACS buffer before being applied to
MACS columns (Miltenyi Biotec) mounted on a magnetic separator
(Miltenyi Biotec). The ﬂow-through was discarded and magnetically
isolated CD14 + monocytes were plunged out of the columns into
separate collection tubes.
Cell culture
Primary human monocytes were seeded in Primaria culture dishes
(BD Falcon, BD Biosciences, Oxford, UK) at 3 9 105 cells/cm2,
and maintained in Roswell Park Memorial Institute medium 1640
(Gibco, Life Technologies); 10% foetal bovine serum (Gibco);
2 mM L-glutamine (Gibco, Life Technologies); 5 U/mL penicillin
and 5 lg/mL streptomycin (Gibco PenStrep solution) in 5% CO2
atmosphere at 37°C. Pre-testing has shown that this protocol
produces monocyte cultures of at least 95% CD14+ monocytes
and these were used in experiments from 1 to 3 days in vitro
(DIV). For some experiments, monocytes were differentiated into
macrophages with the addition of 20 ng/mL granulocyte macro-
phage colony-stimulating factor (GM-CSF, R&D Systems,
Oxford, UK) to the culture medium on seeding. Cells were
given a complete media change with addition of fresh GM-CSF
at 3 DIV and have been conﬁrmed by factor analysis to be fully
differentiated macrophages at 6 DIV and were used in experi-
ments at this stage.
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Cell treatments
Once the cells had adhered post-seeding, monocytes were treated
with doses of laquinimod ranging from 0 to 100 lM for 24 or 48 h
for toxicity analysis. For cytokine analysis, monocytes were treated
with 1 or 5 lM laquinimod for 2 or 24 h, or were untreated. Cells
were then given a media change, and relevant cultures were
stimulated with 1 lg/mL LPS (Sigma, #L6529) for 24 h. 10 ng/mL
interferon gamma (IFNc, R&D Systems) was added at the same
time as LPS as a priming agent. Three drug treatment durations, and
two drug concentrations were used: 2 and 24 h pre-treatments of 1
and 5 lM laquinimod (before stimulation, 2hPT and 24hPT
respectively) and 24 h 5 lM pre-treatment + 24 h continued
5 lM laquinimod treatment during LPS stimulation
(24hPT+24hCT). After LPS stimulation, culture supernatants were
collected, frozen and stored at 80°C. For western blot analysis,
monocytes received 24hPT with 5 lM laquinimod, or untreated,
followed by 1 lg/mL LPS stimulation over a time-course of 0–
60 min. For imaging ﬂow cytometry analysis, monocytes received
24hPT with 5 lM laquinimod, or untreated, before stimulation with
1 lg/mL LPS for 45 min. For proximity ligation assays, macro-
phages were treated with 5 lM laquinimod for 24 h, and then ﬁxed.
Cytotoxicity assay
Monocytes cultures from six HD patients and HV were treated, in
duplicate, with 0, 0.001, 0.01, 0.1, 0.5, 1, 5, 10, 50 or 100 lM
laquinimod for 24 or 48 h. Cell survival after laquinimod treatment
was assessed by CytoTox 96 Non-Radioactive Cytotoxicity Assay
(Promega, Southampton, UK), as per the manufacturer’s protocol,
and compared to viability of untreated cells.
ELISA analysis of cytokines
Cytokine levels in monocyte culture supernatants were measured
using MesoScale Discovery Human Th1/Th2 10-Plex Tissue Culture
Kit analysing 10 different cytokines simultaneously (IFNc, IL-1b,
IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p70, IL-13, TNFa), or Human
IL-6 Singleplex Kit, according to the manufacturer’s protocol.
Depending on cell treatment condition, for 10-plex analysis n = 9–
11 for HV, n = 9 for preHD and n = 10–14 for manHD, and for the
IL-6 singleplex analysis n = 13–15 for HV, n = 6–9 for preHD and
n = 15–19 for manHD. Cytokine level read-outs were normalized to
protein content per culture well, which was ascertained by lysing the
cultures with radioimmunoprecipitation assay buffer [consisting of
25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% Nonidet-P40, 1%
sodium deoxycholate, 0.1% sodium dodecyl sulphate and protease
inhibitor cocktail (Roche, West Sussex, UK)] and performing
bicinchoninic acid protein assays (Pierce, Life Technologies) on the
resulting lysates, according to the manufacturer’s protocol. IFNc
levels were not considered because of the addition of this cytokine as
a priming agent in the stimulated conditions.
Western blotting
Monocyte cultures from four manHD received 24hPT with 5 lM
laquinimod, or untreated, followed by LPS stimulation. Cell lysates
(made using radioimmunoprecipitation assay buffer) were harvested
at 0, 5, 15, 30 and 60 min time-points after stimulation. Protein
lysates were analysed by western blot using anti-IjB antibody
(1:500, Santa Cruz Biotechnology, Heidelberg, Germany) to
determine the rate of IjB degradation. All IjB readings were
normalized to the house-keeping protein glyceraldehyde 3-phos-
phate dehydrogenase (anti-GAPDH antibody, 1:3000, Sigma
Aldrich, Dorset, UK), and quantiﬁed by densitometry analysis of
three exposures using TotalLab TL100 image analysis software
(Sigma Aldrich). Western blotting and analysis were performed as
previously described in detail (Tr€ager et al. 2014).
Imaging flow cytometry
Monocyte cultures from seven manHD received 24hPT with 5 lM
laquinimod, or untreated, followed by 45 min LPS stimulation.
Monocytes were ﬁxed and probed with NFjB p65 XP antibody
(1:200, Cell Signaling Technology, New England Biolabs, Hertford-
shire, UK) followed by secondary anti-rabbit IgG phycoerythrin-
conjugated antibody (1 : 100, eBioscience Ltd., Hatﬁeld, UK). Cells
were stained in 1 lg/mL 40,6-diamidino-2-phenylindole (DAPI,
Sigma Aldrich) nuclear stain immediately prior to analysis. Samples
were run on ImageStreamX analyser (Amnis Corporation, Seattle,
WA, USA) to assess intra/extra-nuclear localization of p65 and
analysed using IDEAS Software (Amnis) to calculate percentage
translocated cells. Imaging ﬂow cytometry and analysis of images
were performed as previously described in detail (Tr€ager et al. 2014).
Proximity ligation assay
Monocytes from six manHD and preHD were seeded on 13 mm
coverslips at 5 9 103 cells/cm2, and differentiated into macro-
phages. Cells were treated with 5 lM laquinimod for 24 h, or
untreated, then ﬁxed in 4% paraformaldehyde and stained with
ﬂuorescent wheat germ agglutinin (WGA, Life Technologies) to
label membranes. Cells were stained with 1 lg/mL WGA for 5 min
at 37°C before washing ten times with phosphate-buffered saline.
Cells were then permeabilized, blocked and probed with mouse anti-
HTT antibody 4C9 (1 : 300, gift from Novartis, Basel, Switzerland)
and anti-IKKc antibody (1 : 100, Santa Cruz). Instead of using
ﬂuorescently labelled secondary antibodies, a proximity ligation
approach was undertaken, as per the manufacturer’s instructions
[Proximity Ligation Assay (PLA), Sigma]. Brieﬂy, samples were
incubated with secondary antibodies conjugated with PLUS and
MINUS DNA probes, which were hybridized and ligated before
ampliﬁcation of the DNA template in a rolling circle ampliﬁcation
reaction. Detection solution was added to identify ampliﬁed DNA,
and coverslips were mounted on glass slides in Duolink mounting
medium (Sigma Aldrich) containing 1 lg/mL DAPI. Signals were
detected using ﬂuorescent confocal microscopy. Positive interac-
tions appear as ﬂuorescent spots which were quantiﬁed as average
number of spots per cell using Volocity software (PerkinElmer,
Waltham, MA, USA). Each of the two negative controls was made
up of a single primary antibody with both PLUS and MINUS
secondary antibodies. The positive control was anti-IKKb (1 : 50;
Santa Cruz) and anti-IKKc primary antibodies with both secondary
antibodies, as these proteins are known to directly interact. PLA and
analysis of images were performed as previously described in detail
(Tr€ager et al. 2014).
Statistical analyses
All samples were labelled with an anonymized 5-digit number for
blinded analysis
Cytotoxicity assay data were statistically analysed in-house. One-
way ANOVA with Dunnett’s multiple comparison tests comparing
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all laquinimod treatment conditions to untreated were used to
analyse statistically signiﬁcant variations in the means.
Analysis of ELISA cytokine measurements was performed by an
independent statistician (RF). The data set was split into two –
stimulated and non-stimulated conditions – to perform statistical
analysis. Not every subject had a measurement for every condition
because of some samples failing quality control, leading to
unbalanced data. Data were log transformed prior to analysis
to improve normality assumptions. A linear mixed model was ﬁtted
to each of the subsets separately, assuming exchangeable correla-
tion, with robust standard errors to allow for misspeciﬁcation of the
covariance structure. Comparisons of interest were calculated using
linear contrasts. This approach allows for data from a subject to be
used even if some of the conditions are missing, under a missing at
random assumption. For the HD combined comparisons, a weighted
combination of preHD and manHD was used, based on the total
number of patients in those subgroups. All analyses were addition-
ally adjusted for age. Multiple comparison adjustments were not
made because of the small sample size and lack of independency in
cytokine activity, and this was taken into consideration when
reviewing the ﬁndings from these analyses. All results of cytokine
levels and statistical analysis of this data are graphically presented
and reported on the logarithmic scale. It is important to note that
natural differences in cytokine release from primary human
monocytes leads to highly variable data, and the sample size limits
the precision for which estimates of between condition and between
group differences can be made. Therefore, in cases where there is
absence of statistical evidence it is not possible to determine whether
this is because of no effect or that the random variation in
measurements masks any effect that may be present.
NFjB mechanism of action data was analysed in-house. IjB
degradation kinetics data were analysed using two-way repeated
measures ANOVA comparing treatment conditions (untreated or
laquinimod pre-treatment) over time post-LPS-stimulation. Two-
tailed, paired Student’s t-tests were used to compare untreated
versus laquinimod treatments for imaging ﬂow cytometry and PLA
data. For PLA analysis, all conditions were tested in six subjects,
however, the results for the laquinimod condition were removed for
one of the subjects for quality control reasons.
Results
Laquinimod is not toxic to ex vivo human monocyte cultures
First, it was important to determine whether laquinimod is
toxic to primary human monocytes in culture. Monocytes
were treated for 24 or 48 h with previously published doses
of laquinimod used to treat human PBMCs, 1 and 5 lM
(Br€uck and Wegner 2011), as well as a range of concentra-
tions either side. Laquinimod-treated cell survival was
assessed relative to untreated cells. None of the laquinimod
concentrations or treatment durations tested showed any
overt toxicity to the cells (Fig. 1). Conﬁdence intervals (CIs,
calculated at the 95% conﬁdence level) around the mean
percentage survival relative to untreated cells span 100%
survival in all laquinimod-treated conditions, and are gener-
ally narrow. In addition, none of the laquinimod treatment
conditions showed a statistically signiﬁcant difference in
percentage monocyte survival (p > 0.05). After the longest
laquinimod treatment duration of 48 h, 1 and 5 lM laquin-
imod resulted in an average of 99.84% and 97.54%
monocyte survival, respectively, relative to untreated cells.
The lower bound of the CIs for these results were 88.01% for
1 lM laquinimod and 86.84% for 5 lM laquinimod, there-
fore one can be conﬁdent that at these concentrations the true
cell survival relative to untreated is above 86%, which was
taken to be acceptable in terms of establishing a lack of
laquinimod toxicity. Previously published doses of 1 and
5 lM laquinimod were therefore used for subsequent
experiments, which is in accordance with physiological
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Fig. 1 Primary human monocyte survival following laquinimod treat-
ment. Monocytes treated with a range of laquinimod concentrations for
24 or 48 h. Laquinimod-treated monocyte survival expressed as a
percentage of untreated monocyte survival. Data points = mean
average of six biological repeats. Error bars = SEM. Concentrations
of 1 and 5 lM (boxed) were used in subsequent experiments.
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in vivo data for relevant plasma levels of laquinimod in
humans (Sennbro et al. 2006; Preiningerova 2009) and mice
(Brunmark et al. 2002).
Laquinimod reduces hyper-reactive cytokine release from
stimulated HD patient monocytes
HD monocytes and macrophages have been observed to
release elevated levels of the proinﬂammatory Th1-activating
cytokines IL-6, IL-8 and TNFa (Bj€orkqvist et al. 2008), and
laquinimod has been reported to drive a shift from Th1- to
Th2-activating cytokine production in human PBMCs
in vitro (Br€uck and Wegner 2011) and in mouse and rat
models of MS in vivo (Zou et al. 2002; Yang et al. 2004;
Br€uck and Wegner 2011). To determine whether laquinimod
can shift the hyper-reactive proinﬂammatory cytokine release
from HD myeloid cells by tipping the reactive cytokine
balance from Th1- to Th2-activating cytokine release, ex vivo
primary monocyte cultures from HV, preHD and manHD
were treated with laquinimod, or untreated, in non-stimulated
and stimulated conditions. Culture supernatants were col-
lected and production of the following cytokines was
measured: Th1-activating cytokines IL-1b, IL-6, IL-8, IL-
12p70, TNFa; Th2-activating cytokines IL-4, IL-5, IL-10,
IL-13, TNFa; and IL-2.
Baseline cytokine release in untreated monocytes
Levels of all cytokines, other than IL-6, were signiﬁcantly
higher (p < 0.05), or borderline, in manHD compared to HV
in monocyte cultures which had received no laquinimod
treatment or stimulation. IL-5, IL-8 and IL-13 were also
elevated in preHD compared to HV under these conditions.
While not all cytokines tested were higher in preHD
compared to HV, both preHD and manHD subgroups
showed similar trends, and combining the HD subjects
increased the power sufﬁciently to see a statistically signif-
icant (p < 0.05), or borderline increase in all cytokines tested
in HD compared to HV cultures (data not shown) suggesting
that HD monocytes inherently release higher levels of
cytokines.
Cytokine release in laquinimod-treated non-stimulated
monocytes
Monocytes from HV showed at least borderline signiﬁcant
evidence for an increase in Th1-activating cytokine IL-12
(p = 0.062) (Figure S1) and the Th2-activating cytokines IL-
4 (p = 0.009) and IL-5 (p = 0.002) (Figure S2), after 2hPT
with 1 lM laquinimod. After 24hPT with 1 lM laquinimod,
IL-4 and IL-5 levels were still estimated to be higher, but to a
lesser degree which was not statistically signiﬁcant. When
HV monocytes were treated with 5 lM laquinimod, there
was evidence of an increase in levels of the Th1-activating
cytokines IL-12 and TNFa (Figure S1) compared to
untreated: IL-12 was increased after 2hPT and
24hPT+24hCT (p = 0.036 and p = 0.026 respectively), and
TNFa was increased after 24hPT and 24hPT+24hCT
(p = 0.022 and p = 0.006 respectively). IL-2 and the Th2-
activating cytokines IL-4, IL-5, IL-10 and IL-13 were also
increased (Figure S2): IL-2 was increased after
24hPT+24hCT (p = 0.030), IL-4 was increased after
24hPT (p = 0.014), IL-5 was increased after 2hPT, 24hPT
and 24hPT+24hCT (p = 0.025, p = 0.002 and p = 0.007
respectively), IL-10 was increased after 24hPT+24hCT
(p = 0.004) and IL-13 was increased after 24hPT+24hCT
(p = 0.005). There was no evidence of a statistically
signiﬁcant effect of laquinimod treatment at any of the
concentrations or treatment durations on non-stimulated
preHD or manHD monocytes.
Cytokine release in non-laquinimod-treated stimulated
monocytes
In LPS(+IFNc)-stimulated conditions, there was some evi-
dence of an increase in IL-1b, IL-5 and IL-13 release in
manHD compared to HV monocytes. The log levels of these
cytokines in manHD were all estimated to be around 0.4
higher than in HV, with these differences being of at least
borderline statistical signiﬁcance. IL-4, IL-6 and IL-10 had
differences in similar magnitude but did not reach borderline
signiﬁcance. IL-8 levels were lower in preHD compared to
HV, with borderline statistical signiﬁcance. Overall there was
little statistical evidence of differences between HD sub-
groups and HV monocyte cytokine release in stimulated
conditions (data not shown).
Cytokine release in 1 lM laquinimod-treated stimulated
monocytes
There was no evidence of an effect of 2hPT with 1 lM
laquinimod in LPS(+IFNc)-stimulated HV monocytes. Fol-
lowing 24hPT at the same concentration, HV monocytes
showed a borderline signiﬁcant increase in Th1-activating
cytokine IL-8 (p = 0.064; Fig. 2) and a signiﬁcant increase in
Th2-activating cytokine IL-5 (p = 0.035; Figure 3) compared
to untreated cells. PreHD subjects showed decreases in Th1-
activating cytokines IL-6 and IL-8 (p = 0.069 and p = 0.004
respectively; Figure 2) compared to untreated, following
2hPT with 1 lM laquinimod. After a longer pre-treatment
duration, 24hPT, at the same concentration, IL-6 levels were
signiﬁcantly decreased compared to untreated (p = 0.028;
Figure 2). Like the preHD group, manHD monocytes also
showed a signiﬁcant decrease in IL-8 levels following 2hPT
with 1 lM laquinimod in stimulated cells (p = 0.005;
Figure 2). There was no statistical evidence of an effect of
1 lM laquinimod on stimulated manHD monocyte cytokine
release following 24hPT (Figures 2 and 3).
Cytokine release in 5 lM laquinimod-treated stimulated
monocytes
In HV monocytes, 2hPT or 24hPT with the higher laquin-
imod concentration of 5 lM resulted in no signiﬁcant effects
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on levels of cytokine release (p > 0.05 for all comparisons;
Figures 2 and 3). Levels of Th1-activating cytokine IL-6
were signiﬁcantly lower in HV monocytes which received
24hPT+24hCT with 5 lM laquinimod compared to untreated
(p = 0.004; Figure 2), and levels of Th2-activating cytokines
IL-5 and IL-13 were signiﬁcantly higher in the same
condition (p = 0.047 and p = 0.041 respectively; Fig. 3).
In the preHD group, although not always statistically
signiﬁcant, the estimates comparing treatments for 2hPT,
24hPT and 24hPT+24CT with the untreated condition
generally showed decreases in levels of cytokines. The
exceptions were IL-2 and IL-5, where the general trend
shows increases in cytokine levels following laquinimod
treatments, but these differences were small in magnitude.
Th1-activating cytokines IL-6 and IL-8 were reduced
(Fig. 2): IL-6 was reduced after 2hPT and 24hPT+24hCT
(p = 0.015 and p = 0.016 respectively), and IL-8 was
reduced after 24hPT (p = 0.015). Th2-activating cytokines
IL-10 and IL-13 were also reduced (Fig. 3): IL-10 was
reduced after 2hPT, 24hPT and 24hPT+24hCT (p = 0.037,
p = 0.015 and p = 0.004 respectively), and IL-13 was
reduced after 24hPT (p = 0.033).
In manHD monocytes, 2hPT with 5 lM laquinimod did
not show a statistically signiﬁcant change in cytokine levels
compared to untreated, however, the 24hPT effect was of at
least borderline statistical signiﬁcance for several cytokines,
with evidence of a reduction in the proinﬂammatory, Th1-
activating cytokines IL-1b (p = 0.022), IL-6 (p = 0.056), IL-
8 (p = 0.052) and TNFa (p = 0.007) (Fig. 2), and the Th2-
activating cytokines IL-5 (p = 0.053), IL-10 (p = 0.044) and
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Fig. 2 Th1-activating cytokine release in stimulated monocytes pre-
treated with laquinimod. Primary stimulated human monocyte cultures
from HV, preHD and manHD received 2hPT or 24hPT with 1 or 5 lM
laquinimod, or 24hPT+24hCT with 5 lM laquinimod. Levels of cytokine
release were measured in monocyte culture supernatants and
normalized to cell culture protein. Figure 2 displays results for the
Th1-activating cytokines and Fig. 3 displays results for IL-2 and the
Th2-activating cytokines measured. Columns = mean average log
cytokine level of biological repeats; error bars = SEM; *p < 0.05,
**p < 0.01.
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IL-13 (p = 0.052) (Fig. 3). In addition, for the cytokines IL-
1b, IL-10 and TNFa, 24hPT with 5 lM laquinimod resulted
in a statistically signiﬁcant reduction in cytokine release from
manHD monocytes that was not seen in HV. While not
statistically signiﬁcant, many of the other cytokines also
showed this trend. This could suggest that 24hPT with 5 lM
laquinimod has more of an effect on reducing cytokine
production in manHD monocytes than in HV monocytes.
After 24hPT+24hCT, there were decreases in the Th1-
activating cytokines IL-6 (p = 0.053), IL-12 (p = 0.028) and
TNFa (p = 0.009) compared to untreated in manHD mono-
cytes (Fig. 2). Although not statistically signiﬁcant, levels of
IL-2 and Th2-activating cytokines IL-4, IL-5 and IL-13 were
increased following 24hPT+24hCT (Fig. 3), going against
the trend seen with 2hPT and 24hPT.
A secondary analysis was performed to increase power and
look at the differences between HV and HD overall. When
manHD and preHD subgroup data were combined, 24hPT
with 5 lM laquinimod resulted in at least a borderline
signiﬁcant decrease in the Th1-activating cytokines IL-1b
(p = 0.006), IL-6 (p = 0.059), IL-8 (p = 0.005) and TNFa
(p = 0.003), and the Th2-activating cytokines IL-10
(p = 0.003) and IL-13 (p = 0.009) compared to the untreated
condition. In addition, the difference in change from the
untreated condition between grouped HD subjects and HV
was of at least borderline signiﬁcance for IL-1b (p = 0.062),
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average log cytokine level of biological repeats; error bars = SEM;
*p < 0.05, **p < 0.01.
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IL-5 (p = 0.045), IL-10 (p = 0.008), IL-13 (p = 0.005) and
TNFa (p = 0.045), suggesting that 24hPT with 5 lM
laquinimod has a larger effect on reducing cytokine release
from HD cells than HV cells.
Laquinimod does not affect NFjB signalling in HD
monocytes
Laquinimod-induced down-regulation of proinﬂammatory
factors in monocytes has previously been shown to be
because of a switch from MI to M2 phenotype (Zou et al.
2002; Yang et al. 2004; Br€uck and Wegner 2011; Schulze-
Topphoff et al. 2012). The exact mechanism for this remains
unclear, although in astrocytes the down-regulation has been
shown to be a result of reduced NFjB activation (Br€uck
et al. 2012). In HD myeloid cells, the enhanced release of
proinﬂammatory factors is at least in part because of elevated
NFjB activation (Tr€ager et al. 2014), so investigations were
made into a role of the NFjB pathway in the observed
overall dampening of cytokine release from stimulated HD
monocytes pre-treated with laquinimod.
To determine whether laquinimod has the potential to
improve NFjB dysfunction in HD, the effect of the
compound on IjB degradation kinetics was assessed in HD
monocytes. IjB binds NFjB transcription factor p65 in the
cytoplasm, preventing its nuclear translocation. Degradation
of IjB, however, liberates p65, which then translocates into
the nucleus to modulate transcription (Hayden and Ghosh
2012). Consequently, monitoring IjB kinetics is an indirect
measure for monitoring p65 nuclear translocation; decreased
IjB levels indicates increased nuclear translocation of p65.
ManHD monocytes were stimulated with LPS, with or
without 24hPT with 5 lM laquinimod, and IjB levels were
measured by western blotting at 0, 5, 15, 30 and 60 min post-
stimulation. LPS stimulation resulted in the usual degrada-
tion pattern of IjB for HD monocytes (Tr€ager et al. 2014),
and laquinimod pre-treatment did not signiﬁcantly alter
(p = 0.566) IjB levels from the untreated condition over
time post-LPS stimulation (Fig. 4a). As IjB degradation
kinetics were not affected by laquinimod treatment, this
suggests that laquinimod may not alter nuclear translocation
of the NFjB transcription factor p65 in monocytes. How-
ever, because of the indirect method of measuring p65
translocation used, it was necessary to directly monitor
nuclear translocation using an alternative method before
ruling out an effect of laquinimod in this mechanism.
Imaging ﬂow cytometry was implemented to directly
assess p65 nuclear translocation. ManHD monocytes
received 24hPT with 5 lM laquinimod, or untreated, for
24 h before 45 min LPS stimulation. Monocytes were
labelled with anti-p65 antibody and DAPI nuclear stain,
and run through ImageStream to detect intra/extra-nuclear
localization of p65. NFjB translocation has previously been
shown to be pathologically enhanced in HD patient myeloid
cells, leading to a hyper-reactive response to LPS stimulation
and increased release of proinﬂammatory cytokines (Tr€ager
et al. 2014). 24hPT with 5 lM laquinimod did not signif-
icantly alter (p = 0.466) the extent of p65 translocation
compared to untreated in HD monocytes (Fig. 4b).
It has previously been shown in HD myeloid cells that
mHTT directly interacts with the c subunit of IKK, and it is
this dysfunctional interaction which may lead to the observed
increase in IjB degradation (Tr€ager et al. 2014). PLA was
conducted to assess the interaction between mHTT and IKKc
in HD macrophages after 24hPT with 5 lM laquinimod, or
untreated. Laquinimod did not signiﬁcantly alter (p = 0.552)
the number of observed positive HTT-IKKc interactions
(spots per cell) compared to untreated, suggesting that
laquinimod does not affect the interaction between mHTT
and IKKc in HD macrophages (Fig. 4c).
Discussion
Systemic levels of proinﬂammatory cytokines in HD gene
carriers are elevated many years before disease manifesta-
tion, and monocytes and macrophages are the likely source
(Bj€orkqvist et al. 2008). HD patient monocytes produce
higher levels of cytokines than HV monocytes when
stimulated ex vivo (Bj€orkqvist et al. 2008) and are impaired
in their ability to migrate towards chemoattractant stimuli
(Kwan et al. 2012b). There is evidence that systemic
inﬂammatory processes activate CNS microglia leading to
exacerbation of neurodegeneration pathology (Cunningham
et al. 2007; Perry 2007; Perry et al. 2007; Palin et al. 2008),
and peripheral immune challenges have been shown to
exacerbate disease progression in mouse models of HD
(Hsiao et al. 2013). Therefore, peripheral immune events
may directly inﬂuence neuroinﬂammation and neuropathol-
ogy in HD.
Laquinimod appears to alter hyperactivity of the peripheral
immune system in HD as shown by its reduction in cytokine
release from HD patient blood-derived monocytes. In non-
stimulated conditions, laquinimod showed signiﬁcant effects
on HV cytokines but not preHD or manHD cytokine levels.
In stimulated monocytes, laquinimod had an overall damp-
ening effect on cytokine release; however, these changes
were variable depending on the cytokine, subject group, and
laquinimod pre-treatment conditions. Laquinimod pre-treat-
ment reduced the release of nearly all cytokines from
stimulated preHD and/or manHD monocytes compared to the
untreated condition. This effect was most consistent follow-
ing 24hPT, and interestingly had an effect of larger
magnitude on HD monocytes than on HV monocytes, where
the changes (if any) in the HV group were relatively minor.
In particular, our data provides evidence for this for the Th1-
activating proinﬂammatory cytokines IL-1b, IL-8 and TNFa
and the Th2-activating cytokines IL-5, IL-13 and anti-
inﬂammatory IL-10. It is important to note that the natural
differences in cytokine release from primary human mono-
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Fig. 4 Laquinimod does not affect (a) IjB degradation kinetics, (b) p65
translocation or (c) IKKc-mHTT interaction in HD patient myeloid cells.
(a) IjB degradation kinetics in lipopolysaccharide (LPS)-stimulated HD
monocytes, with and without 24hPT with 5 lM laquinimod. IjB levels
measured using western blotting of cell lysates harvested at 0, 5, 15,
30 and 60 min post-LPS stimulation. Blots quantiﬁed using densitom-
etry giving a procedure deﬁned unit (p.d.u.) for comparison of
conditions. Columns = mean average p.d.u. of four biological repeats;
error bars = SEM. (b) Nuclear translocation of NFjB transcription
factor p65 in manHD monocytes 45 min post-LPS stimulation, as
assessed by imaging ﬂow cytometry. Monocytes received 24hPT with
5 lM laquinimod or untreated. Monocytes were probed for p65 (green)
and nuclei were stained with DAPI (pink), as can be seen in example
images all taken from the same untreated sample, and percentage
translocated cells assessed. Columns = mean average percentage
translocated cells from seven biological repeats; error bars = SEM. (c)
Interaction between HTT and IKKc in HD macrophages with or without
24 h 5 lM laquinimod treatment, as assessed by proximity ligation
assay (PLA). Cells imaged using ﬂuorescence confocal microscopy. A
direct interaction between the two proteins is presented as a
ﬂuorescent red spot, nuclei stained with DAPI (blue) and membranes
withwheat germ agglutinin (WGA) (green), as can be seen in example
images all taken from the same patient cells. Positive and negative
controls indicate success of the assay. Columns = mean average
spots per cell (untreated condition from 6 biological repeats, laquin-
imod condition from ﬁve biological repeats; ﬁve matched pairs); error
bars = SEM.
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cytes (HV and HD) leads to large variations in cytokine level
measurements, which introduces some limitations to this
system. Consequently, it is not always possible to determine
whether lack of a statistically signiﬁcant effect is because of
there being no effect or because of random variation in
measurements masking an effect that may be present.
Overall, the sample size limits the precision for which
between condition and between subject group differences can
be assessed. However, there is evidence that laquinimod does
have an effect on cytokine release from HD monocytes, and
that this effect may be different than the effect of laquinimod
on HV monocytes.
Cytokine level trends across laquinimod treatment condi-
tions are generally consistent in terms of laquinimod-induced
changes being greater in magnitude at the 5 lM drug
concentration and a longer pre-treatment duration. However,
this did not usually extend to the 24hPT+24hCT condition,
where in many cases a much smaller change from the
untreated condition occurred than would have been pre-
dicted, or there was even a change in the opposite direction.
Indeed, with the exception of IL-10, there were small
increases in the Th2-activating cytokines in the
24hPT+24hCT condition. Thus, it is important to note that
the 24hPT+24hCT condition may need to be considered
independently from the pre-treatment only conditions, as
laquinimod was present during stimulation. It is possible that
an alternative mechanism of action is at play under these
conditions, such as competitive binding or confounding cross
talk between intracellular signalling pathways.
We did not observe an overall shift in cytokine balance
from Th1- to Th2-activating cytokine release in HD mono-
cytes, which has been reported previously in MS (Zou et al.
2002; Yang et al. 2004; Br€uck and Wegner 2011; Schulze-
Topphoff et al. 2012). The shift in cytokine balance
previously reported was identiﬁed in systems quite different
than those used here. Zou et al. (2002) and Yang et al.
(2004) both describe a decrease in proinﬂammatory cytoki-
nes along with an increase in Th2-activating and anti-
inﬂammatory cytokines in vivo in rat models of MS
following 15 days of daily laquinimod administration. Zou
et al. found a decrease in the number of IFNc- and TNFa-
expressing cells, with an increase in the number of IL-4-
expressing cells in sciatic nerve sections, but in mononuclear
cells (MNCs) isolated from lymph node they only looked at
release of the proinﬂammatory cytokines, which decreased.
Yang et al. describe an increase in the number of spleen
MNCs expressing mRNA for the Th2-activating cytokines
IL-4, TGFb1 and IL-10 and a decrease in the number of cells
expressing mRNA for proinﬂammatory IL-12 and TNFa,
however, in PBMCs they report a decrease in the number of
cells expressing TNFa mRNA with no change in the other
cytokines. Schulze-Topphoff et al. (2012) also report their
ﬁndings in an in vivo animal model of MS, describing a
laquinimod-induced cytokine shift in cells isolated from
spleen. Br€uck and Wegner (2011) report a Th1- to Th2-
activating shift following daily laquinimod administration in
a MS mouse model, but in PBMCs isolated from HVs they
only describe decreases in proinﬂammatory cytokines. In our
model, we push isolated PBMCs towards an M1 phenotype
by stimulating them with LPS and IFNc. In this setting an
increase in Th2-activating cytokines was unlikely to be
observed, however, laquinimod pre-treatment did reduce
overall cytokine production, including those which promote
Th1 activation, suggesting that the functional signatures of
laquinimod-treated HD monocytes are somewhere between
the M1 and M2 polarization extremes following stimulation
(Martinez and Gordon 2014). Overall, our evidence for a
laquinimod-induced decrease in cytokine release from human
HD monocytes is supported by the current literature on
laquinimod effects in MS models. Our ﬁndings for lack of a
Th1- to Th2-activating shift in cytokine balance is also
consistent with the effects seen following laquinimod pre-
treatment of LPS-activated human microglial cultures, where
laquinimod signiﬁcantly reduced the secretion of the proin-
ﬂammatory cytokines TNFa, IL-1b, IL-12p70 and IL-6, and
the anti-inﬂammatory/regulatory cytokines IL-4, IL-10 and
IL-1ra (Mishra et al. 2014).
In the Bj€orkqvist et al. (2008) study comparing peripheral
cytokine levels in the plasma of HV and HD patient
subgroups, there were increased levels of both Th1- and
Th2-activating cytokines in HD compared to HV, and these
increases correlated with disease progression. The Th1-
activating cytokines IL-6, IL-8 and TNFa, and the Th2-
activating cytokines IL-4 and anti-inﬂammatory IL-10 were
elevated in HD patient plasma compared to HV plasma. A
combination of IL-6, IL-8 and IL-10 cytokine increases was
positively correlated with disease progression from preHD
through to manHD, and could also be used to discriminate
HV from HD gene carriers (both pre-manifest and manifest).
In this study, laquinimod shows dampening of the hyper-
reactive release of cytokines by HD monocytes, and this may
be a way of reducing the elevated plasma cytokine levels
observed in HD patients and the increasing levels in
advancing disease, both peripherally and in the brain.
It may seem counterintuitive to reduce potent proinﬂam-
matory factors such as IL-1b and TNFa whilst additionally
decreasing the key anti-inﬂammatory cytokine IL-10. How-
ever, IL-10 levels, which are shown to be high in HD
patients, are also abnormally elevated in Alzheimer’s disease
(AD) patient brains (Guillot-Sestier et al. 2015), and IL-10
has recently been highlighted as harmful in mouse models of
AD; increasing brain amyloid-b (Ab) accumulation, exacer-
bating memory impairment and suppressing microglial Ab
phagocytosis (Chakrabarty et al. 2015). As HD and AD
share similar pathologies of protein aggregation and neu-
rodegeneration, and are both diseases exacerbated by
dysregulated inﬂammation, it may be that the laquinimod-
induced reduction in IL-10 from HD peripheral myeloid cells
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is beneﬁcial, and may contribute to resolution of the innate
immune system cytokine balance.
Previous studies on laquinimod mechanism of action
present evidence for a role of the NFjB pathway in
astrocytes. Laquinimod reduced astrocytic NFjB activation
in cuprizone-treated mice and primary human astrocyte
cultures (Br€uck et al. 2012), and gene expression microar-
rays on laquinimod-treated PBMCs isolated from MS
patients revealed down-regulation of key genes downstream
of NFjB signalling (Gurevich et al. 2010). The results of
this study, however, do not support a role for laquinimod
mechanism of action downstream of NFjB activation in
primary human HD monocytes. Laquinimod did not affect
IjB degradation kinetics, nuclear translocation of p65 nor
IKKc-mHTT protein–protein interactions, from the untreated
condition. This is in accordance with work by Br€uck et al.
who found that NFjB activation was markedly reduced by
laquinimod in astrocytes, but not in microglia, the resident
myeloid cells of the CNS, in stimulated primary mouse
cultures (Br€uck et al. 2012).
In summary, 5 lM laquinimod applied to HD patient
peripheral myeloid cells for 24 h appears to reduce hyper-
reactive cytokine production in response to LPS stimulation.
This is true for Th1-activating proinﬂammatory cytokines
and Th2-activating cytokines including IL-10. Altering
peripheral immune responses modulates central pathology
and disease progression in HD, hence laquinimod is a
promising candidate for dampening the harmful effects of a
dysfunctional innate immune system in HD. The mechanism
for this does not appear to be downstream of NFjB
activation in these cells. Laquinimod mechanism of action
is currently under investigation.
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